Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBR-01
- Development stage
- Preclinical
- Lead developer
- ASST Cremona
- Modality
- Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**MBR-01** is a standardized oral mixed probiotic/prebiotic dietary supplement studied as supportive prophylaxis for abemaciclib-associated diarrhea in patients with high-risk, hormone receptor-positive, HER2-negative early breast cancer receiving adjuvant abemaciclib plus letrozole. It is intended to modulate and stabilize the gut microbiota, thereby limiting treatment-associated dysbiosis and gastrointestinal toxicity. In a small single-center prospective case-control study, MBR-01 was associated with reduced diarrhea frequency and severity, preserved microbial diversity, improved quality-of-life measures, and maintenance of abemaciclib dose intensity; the evidence base remains limited to this pilot study. ([medrxiv.org](https://www.medrxiv.org/content/10.64898/2026.02.13.26346277v1))
- Other names
- MBR 01MBR01MBR-01
Beyond the preview
Go deeper on MBR-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBR-01.